Publications

5803 Results

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Authors
T Parker;A Rosenthal;V Sanchorawala;H Landau;E Campagnaro;P Kapoor;N Neparidze;S Girnius;P Hagen;E Scott;A Hoering;B Durie;R Orlowski
Journal / Conference
Blood Sep 9:blood.2024027962
Year
2025
Research Committee(s)
Myeloma
PMID
PMID40925099
Study Number(s)
S1702

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Authors
P Torka;A Bock;E Nazarenko;Y Xu;J Vaughn;S Thiruvengadam;A Major;K Sekaran;D Reef;C Lee;G Smilnak;E Luttwak;V Patel;H Shah;A Ip;G Baek;R Mynam;D Sano;D Gerber;A Falade;M Palmeri;R Mrad;M Iqbal;J Sharp;T Voorbees;P Geethakumari;J Rbodes;U Durani;H Cherng;Y Karimi;P Pophali;M Di;T Feldman;J Svoboda;K Shanmugasundaram;A Niu;N Grover;R Karmali;A Herrera;C Diefenbach;N Epperla
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #3622 poster
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)

Authors
C Casulo;H Li;A Herrera;S Castellino;S Rutherford;K Davison;A Punnett;B Kahl;J Leonard;S Smith;J Song;K Kelly;J Friedberg;M LeBlanc;S Parsons;A Rodday;A Evens
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL), #154 oral
Year
2025
Research Committee(s)
Lymphoma

Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch

Authors
S Jiwani;M Fang;C Yeung;X QU;X Chen;B Wood;A Zak
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #3622, #340, oral
Year
2025
Research Committee(s)
Leukemia

Emerging strategies for drug-based cancer risk reduction

Authors
Daca-Alvarez M
Journal / Conference
Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473708
Year
2025
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Inclusive Cancer Clinical Trial Participation – A Recipe for New Treatment Advances

Authors
Unger JM
Journal / Conference
JAMA Netw Open. 2025 Jun 2;8(6):e2515210
Year
2025
Research Committee(s)
Cancer Care Delivery

Financial toxicity: A ubiquitous condition in patients with cancer

Authors
Unger JM
Journal / Conference
Cancer. 2025 Feb 15;131(4):e35748
Year
2025
Research Committee(s)
Cancer Care Delivery

Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups

Authors
TJ Hoffman
Journal / Conference
Nat Genet, 57(2), 334-344
Year
2025
Research Committee(s)
Cancer Control, Prevention, Screening, and and Surveillance
Study Number(s)
S0000, SWOG-9217

Long-term effect estimation when combining clinical trial and observational follow-up datasets

Authors
Chen G
Journal / Conference
J Amer Stat Assoc. 2025 Jul 15:1-10
Year
2025
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratification – an NCI myeloMATCH and SWOG report

Authors
Min Fang, MD, PhD
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #3501
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
MYELOMATCH